Business Description
Axsome Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05464T1043
Total Employee Number:
925Description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.39 | |||||
Equity-to-Asset | 0.08 | |||||
Debt-to-Equity | 4.03 | |||||
Debt-to-EBITDA | -1.26 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 9.04 | |||||
Beneish M-Score | -2.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.5 | |||||
3-Year EBITDA Growth Rate | 7.8 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 13.2 | |||||
3-Year Book Growth Rate | -11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 55.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.27 | |||||
9-Day RSI | 60.91 | |||||
14-Day RSI | 68.45 | |||||
3-1 Month Momentum % | 47.73 | |||||
6-1 Month Momentum % | 56.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.39 | |||||
Quick Ratio | 1.32 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 164.33 | |||||
Days Sales Outstanding | 106.4 | |||||
Days Payable | 562.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -0.61 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.6 | |||||
Operating Margin % | -24.93 | |||||
Net Margin % | -26.59 | |||||
EBITDA Margin % | -24.6 | |||||
FCF Margin % | -10.07 | |||||
OCF Margin % | -10.03 | |||||
ROE % | -274.58 | |||||
ROA % | -28.45 | |||||
ROIC % | -89.07 | |||||
3-Year ROIIC % | 6.61 | |||||
ROC (Joel Greenblatt) % | -823.22 | |||||
ROCE % | -59.4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 248.31 | |||||
PS Ratio | 17.15 | |||||
PB Ratio | 227.04 | |||||
Price-to-Tangible-Book | 3603.33 | |||||
EV-to-EBIT | -67.15 | |||||
EV-to-Forward-EBIT | 130.06 | |||||
EV-to-EBITDA | -70.73 | |||||
EV-to-Forward-EBITDA | 116.78 | |||||
EV-to-Revenue | 17.4 | |||||
EV-to-Forward-Revenue | 12.85 | |||||
EV-to-FCF | -173.58 | |||||
Price-to-GF-Value | 1.09 | |||||
Earnings Yield (Greenblatt) % | -1.49 | |||||
FCF Yield % | -0.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Axsome Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 608.545 | ||
| EPS (TTM) (€) | -3.21 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 68.45 | ||
| 14-Day ATR (€) | 2.502771 | ||
| 20-Day SMA (€) | 212.8175 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 104.15 - 218.2 | ||
| Shares Outstanding (Mil) | 51.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axsome Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Axsome Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 08:00 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:00 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 34 days | ||
| Guidance call for 2026 | 2026-06-15 11:30 | 218.20 (+0.00%) | ||
| Oppenheimer CNS and Neuro-Muscular Summit | 2026-06-10 14:00 | 202.40 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 15:20 | 202.40 (+0.00%) | ||
| General meeting for 2026 | 2026-06-05 09:00 | 202.40 (+0.50%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 10:30 | 194.25 (-0.26%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-03 15:40 | 191.10 (-1.75%) |
Show
Entries
Axsome Therapeutics Inc Frequently Asked Questions
What is Axsome Therapeutics Inc(MIL:1AXSM)'s stock price today?
The current price of MIL:1AXSM is €214.70. The 52 week high of MIL:1AXSM is €218.20 and 52 week low is €104.15.
When is next earnings date of Axsome Therapeutics Inc(MIL:1AXSM)?
The next earnings date of Axsome Therapeutics Inc(MIL:1AXSM) is 2026-08-04 Est..
Does Axsome Therapeutics Inc(MIL:1AXSM) pay dividends? If so, how much?
Axsome Therapeutics Inc(MIL:1AXSM) does not pay dividend.
Press Release
Articles on Axsome Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers